Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PPCB

Propanc Biopharma Inc

May 01 • 11:45AM ET

0.1070

+0.0054 5.31 %

Healthcare • Biotechnology • Australia • Nano • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.54	Insider Own	37.56%	Shs Outstand	21.86M	Perf Week	-2.64%
Market Cap	2.34M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	13.65M	Perf Month	-4.21%
Enterprise Value	3.43M	PEG	-	EPS next Q	-	Inst Own	0.59%	Short Float	1.48%	Perf Quarter	-53.03%
Income	-67.00M	P/S	-	EPS this Y	-	Inst Trans	0.83%	Short Ratio	0.05	Perf Half Y	-91.83%
Sales	0.00M	P/B	0.14	EPS next Y	-	ROA	-869.88%	Short Interest	0.20M	Perf YTD	-80.06%
Book/sh	0.78	P/C	4.17	EPS next 5Y	-	ROE	-2099.56%	52W High	10.81 -99.01%	Perf Year	-97.32%
Cash/sh	0.03	P/FCF	-	EPS past 3/5Y	98.29% 98.33%	ROIC	-583.24%	52W Low	0.09 12.63%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.46% 15.22%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	97.95%	Oper. Margin	-	ATR (14)	0.01	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.13	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.98	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.13	EPS Q/Q	99.09%	SMA20	-1.91%	Beta	3.40	Target Price	380.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-17.96%	Rel Volume	0.17	Prev Close	0.10
Employees	2	LT Debt/Eq	0.10	Earnings	-	SMA200	-93.24%	Avg Volume	4.03M	Price	0.11
IPO	Nov 12, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	265,929	Change	5.31%

Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +13.44%
Mar-24-26 08:45AM	Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaen and Granada, Spain (GlobeNewswire) -5.94%
Mar-12-26 08:45AM	Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy (GlobeNewswire) -13.57%
Mar-10-26 08:45AM	Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study (GlobeNewswire) -20.47%
Mar-03-26 08:45AM	Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models (GlobeNewswire) -5.16%
08:45AM	Loading…
Feb-18-26 08:45AM	Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results (GlobeNewswire)
Feb-05-26 08:45AM	Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market (GlobeNewswire) +5.71%
Jan-27-26 08:45AM	Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations (GlobeNewswire) +6.52%
Jan-20-26 08:45AM	Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia (GlobeNewswire)
Jan-15-26 08:45AM	Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer (GlobeNewswire) -17.13%
Jan-13-26 08:45AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Dec-22-25 07:00AM	Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal (GlobeNewswire) -8.45%
Dec-04-25 08:45AM	Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs (GlobeNewswire)
Dec-01-25 08:45AM	Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis (GlobeNewswire) +5.47%
Nov-17-25 08:45AM	Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results (GlobeNewswire)
08:45AM	Loading…
Nov-10-25 08:45AM	Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline (GlobeNewswire) -12.43%
Nov-04-25 07:00AM	Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) (GlobeNewswire) -6.19%
Oct-15-25 05:45PM	CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire) -8.67%
08:45AM	Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital (GlobeNewswire)
Oct-07-25 08:45AM	Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy (GlobeNewswire)
Sep-17-25 08:45AM	Propanc Biopharma Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office (GlobeNewswire)
Sep-02-25 09:00AM	Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum (GlobeNewswire) -9.60%
Aug-25-25 07:30AM	Propanc Biopharma Provides Shareholder Update (GlobeNewswire)
Aug-19-25 08:30AM	Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ (GlobeNewswire) -37.26%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +103.83%
Aug-14-25 11:00PM	Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering (GlobeNewswire) +30.00% -72.40%

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PPCB

Propanc Biopharma Inc

Upgrade your Finviz experience